TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update
30 Octubre 2023 - 5:30AM
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a
conference call will be held on Wednesday, November 1, 2023, at
8:30 AM ET to discuss results for the third quarter 2023 and
provide a business outlook for remainder of the year. Michael S.
Weiss, Chairman and Chief Executive Officer of TG Therapeutics,
will host the call.
In order to participate in the conference call, please call
1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.),
Conference Title: TG Therapeutics. A live webcast of this
presentation will be available on the Events page, located within
the Investors & Media section, of the Company's website at
www.tgtherapeutics.com. An audio recording of the conference call
will also be available for replay at www.tgtherapeutics.com, for a
period of 30 days after the call.
TG Therapeutics will announce its financial results for this
period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICSTG Therapeutics is a
fully integrated, commercial stage, biopharmaceutical company
focused on the acquisition, development and commercialization of
novel treatments for B-cell diseases. In addition to a research
pipeline including several investigational medicines, TG has
received U.S. Food and Drug Administration (FDA) approval for
BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients
with relapsing forms of multiple sclerosis (RMS), to include
clinically isolated syndrome, relapsing-remitting disease, and
active secondary progressive disease as well as European Commission
(EC) approval for BRIUMVI to treat adult patients with RMS who have
active disease defined by clinical or imaging features. For more
information, visit www.tgtherapeutics.com, and follow us on
Twitter @TGTherapeutics and on LinkedIn.CONTACT:
Investor Relations Email: ir@tgtxinc.comTelephone:
1.877.575.TGTX (8489), Option 4
Media Relations: Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
TG Therapeutics (NASDAQ:TGTX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
TG Therapeutics (NASDAQ:TGTX)
Gráfica de Acción Histórica
De May 2023 a May 2024